Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Can Inovio Recover From Its Huge Setback?

TheMotleyFool

0 0

Can Inovio Recover From Its Huge Setback?

Inovio Pharmaceuticals (NASDAQ: INO) hasn't ranked among the leaders in the COVID-19 vaccine race so far. However, the small biotech has been a definite contender in the second tier of vaccine makers. Inovio hoped to separate from the pack by delivering impressive results with a planned late-stage study of its COVID-19 vaccine candidate INO-4800.

That plan just ran into a major obstacle, though. Inovio announced last Friday that the U.S. Department of Defense has decided not to fund the company's phase 3 study. The news caused the biotech stock to plunge 26%. Can Inovio recover from its huge setback?

Image source: Getty Images.

Source Fool.com

Like: 0

INO

Share